Natixis Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Natixis Advisors LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.0% in the fourth quarter, Holdings Channel reports. The fund owned 109,938 shares of the biopharmaceutical company’s stock after selling 7,064 shares during the quarter. Natixis Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $78,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Amundi increased its stake in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth $127,489,000. KBC Group NV increased its stake in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $65,180,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $666.87 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $72.91 billion, a PE ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27. The business has a 50-day simple moving average of $694.91 and a two-hundred day simple moving average of $833.75. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the company earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analysts Set New Price Targets

A number of research firms have weighed in on REGN. Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.